AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
Log in

NASDAQ:SYBXSynlogic Stock Price, Forecast & News

$2.44
0.00 (0.00 %)
(As of 05/27/2020 12:11 PM ET)
Add
Compare
Today's Range
$2.32
Now: $2.44
$2.46
50-Day Range
$1.60
MA: $2.09
$2.43
52-Week Range
$1.35
Now: $2.44
$10.01
Volume200,076 shs
Average Volume270,606 shs
Market Capitalization$80.14 million
P/E RatioN/A
Dividend YieldN/A
Beta2.17
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Read More
Synlogic logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.64 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYBX
CUSIPN/A
Phone617-401-9975

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.22 million
Book Value$4.33 per share

Profitability

Net Income$-51,370,000.00
Net Margins-2,733.25%

Miscellaneous

Employees74
Market Cap$80.14 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive SYBX News and Ratings via Email

Sign-up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.

Synlogic (NASDAQ:SYBX) Frequently Asked Questions

How has Synlogic's stock been impacted by COVID-19 (Coronavirus)?

Synlogic's stock was trading at $1.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SYBX stock has increased by 58.4% and is now trading at $2.44. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Synlogic?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Synlogic.

When is Synlogic's next earnings date?

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Synlogic.

How were Synlogic's earnings last quarter?

Synlogic Inc (NASDAQ:SYBX) announced its quarterly earnings data on Friday, May, 8th. The biotechnology company reported ($0.46) EPS for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.03. The biotechnology company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.73 million. Synlogic had a negative net margin of 2,733.25% and a negative return on equity of 33.46%. View Synlogic's earnings history.

When did Synlogic's stock split? How did Synlogic's stock split work?

Synlogic's stock reverse split on the morning of Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SYBX?

6 brokerages have issued 1-year target prices for Synlogic's shares. Their forecasts range from $2.00 to $25.00. On average, they anticipate Synlogic's share price to reach $13.40 in the next twelve months. This suggests a possible upside of 449.2% from the stock's current price. View analysts' price targets for Synlogic.

Has Synlogic been receiving favorable news coverage?

News articles about SYBX stock have trended very negative on Wednesday, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Synlogic earned a media sentiment score of -3.1 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutSynlogic.

Who are some of Synlogic's key competitors?

What other stocks do shareholders of Synlogic own?

Who are Synlogic's key executives?

Synlogic's management team includes the following people:
  • Dr. Peter Barrett, Exec. Chairman (Age 66)
  • Dr. José Carlos Gutierrez-Ramos, Advisor (Age 56)
  • Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Pres, CEO, Chief Medical Officer & Director (Age 43)
  • Prof. Timothy K. Lu, Co-Founder
  • Dr. James J. Collins, Co-Founder

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Who are Synlogic's major shareholders?

Synlogic's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Two Sigma Investments LP (1.14%), JPMorgan Chase & Co. (1.14%), Two Sigma Advisers LP (0.99%), State Street Corp (0.93%), Geode Capital Management LLC (0.86%) and Parametric Portfolio Associates LLC (0.43%). Company insiders that own Synlogic stock include Paul Francis Miller and Richard P Shea. View institutional ownership trends for Synlogic.

Which major investors are selling Synlogic stock?

SYBX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Alambic Investment Management L.P., and Two Sigma Investments LP. View insider buying and selling activity for Synlogic.

Which major investors are buying Synlogic stock?

SYBX stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Parametric Portfolio Associates LLC, Los Angeles Capital Management & Equity Research Inc., Geode Capital Management LLC, Connor Clark & Lunn Investment Management Ltd., Wells Fargo & Company MN, JPMorgan Chase & Co., and State Street Corp. View insider buying and selling activity for Synlogic.

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $2.44.

How big of a company is Synlogic?

Synlogic has a market capitalization of $80.13 million and generates $2.22 million in revenue each year. The biotechnology company earns $-51,370,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Synlogic employs 74 workers across the globe.

What is Synlogic's official website?

The official website for Synlogic is www.synlogictx.com.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.